Incorporation of potent and selective cytochrome P450 1B1 inhibitors into Ru(II) scaffolds provides unprecedented control over enzyme activity with light

The cytochrome P450 family of enzymes (CYPs) are important targets for medicinal chemistry. Recently, CYP1B1 has emerged as a key player in chemotherapy resistance in the treatment of cancer. This enzyme is overexpressed in a variety of tumors, and is correlated with poor treatment outcomes; thus, it is desirable to develop CYP1B1 inhibitors to restore chemotherapy efficacy. However, possible off-target effects, such as inhibition of liver CYPs responsible for first pass metabolism, make selective inhibition a high priority to avoid possible drug-drug interactions and toxicity. Here we describe the creation of light-triggered CYP1B1 inhibitors as “prodrugs”, and achieve >6,000-fold improvement in potency upon activation with low energy (660 nm) light. The novel systems provide a selectivity index of 4,000–100,000 over other off-target CYPs. One key to the design was the development of novel, coordinating CYP1B1 inhibitors which suppress enzyme activity at pM concentrations in live cells. The coordinating group enforces inhibitor orientation in the active site by anchoring to the iron. The second essential component was the biologically compatible Ru(II) scaffold that cages the inhibitors before photochemical release. These Ru(II) photocages are anticipated to provide similar selectivity and control for any coordinating CYP inhibitors.